Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
If the trial is successful then they would outsource the phase 3 trial. I forget the name of the firm but I also think it's quoted.
I expect it would complete later in the year.
I suspect if p2 is successful there would be a degree of authorization for use.
Never heard of Degiro. I use HL and ii.
They are ok, worth talking to a dealer to get an idea of how competent they are. Also ask them about how many RSPs they have on their automated system.
At a large brokerage firm there will be many inexperienced call center staff and a few old time dealers. I know ii have a few from pre tech bubble dealers who know how to deal.
Don't be fobbed off by someone who doesn't sound as if know what they are on about and asked to be put through to a senior dealer.
If you don't like a price that it has been dealt at dispute it and don't trade large trades automatically unless you see a price inside the spread.
That question only you can answer as everyone's circumstances and tolerance to risk is different.
If it is an amount you are 'playing' with is different to investing an amount you would worry about losing.
If it is causing you worry it is probably too much.
Did anyone catch the lecture the CMO Dr Chris Whitty gave on Covid last night on the Parliament Channel
He reviewed where we are as a nation.
https://www.bbc.co.uk/iplayer/episode/m000j8cl/briefings-dr-chris-whitty
At about 1 hr 10ins he reviewed drug option.
Although he did not mention SNG001 he list the types of drugs which show promise and outlined the danger of not testing drugs properly. He highlights that Chloro quinine actually increase the death rate.
Yep
I must admit I have spoken to some fund managers who hold the stock who reminded me of risks in phase 2 and 3. The upside is much greater than I thought , but the risks are as well.
Institutions are in part guided by the FinnCap valuation. That could drive the price.
Rahul
I agree it looks promising, but there may be bumps in the road.
There are many firms racing to develop drugs. Someone may beat us.
The drug might not be quite as effective in late delivered treatment.
The cost to development into phase 3 may require further capital raise.
Other reasons..
Just saying consider the risk as well as benefits as failure will wipe 90% + value from the firm. DYOR and size position accordingly.
I looked at the cost of interferon beta in the us and it's huge... Over $4k per dose. So if it works it will head high depending on how positive the results are. The phase 3 trial might be shortened but still take a while. If News is bad.....well there is about 8p of cash on the balance sheet.
Colber
Forecasting is a dark art. For biotech stocks it more like guess work.
If the drug works, (might not) how many units could a Synairgen make? Could they manage to sell it globally?
There are only 16 employee. So they could license it to a bigger firm who has the reach and resources to send it global. SNG would get a slice of each sale, bit the pie would be larger. The share price can be determined as on many metrics. Price to sales, price to earnings etc.
Or a big firm like AZN could come in and buy it out